Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,033 USD | +0.92% |
|
-1.72% | +17.61% |
07-03 | Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval | MT |
07-03 | Sanofi obtains EU approval for Dupixent | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.61% | 110B | |
+16.87% | 121B | |
+17.23% | 25.98B | |
-24.41% | 19.27B | |
-18.56% | 15.99B | |
-18.60% | 15.66B | |
-47.75% | 14.5B | |
+56.92% | 14.47B | |
+5.46% | 13.91B | |
+116.51% | 10B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 02